There have been no clinically applicable variations in comparison with 2011 apart from new data and new recommendations with regard to the remedy with bisphosphonates and denosumab (see segment ‘Bisphosphonates and RANKL Antibody Denosumab’).element is existing or not. The prerequisites for just a specific axillary dissection have been also des